A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

Overview of attention for article published in BMC Cancer, May 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

patent: 16 patents

guideline: 1 clinical guideline source

Readers on

mendeley: 135 Mendeley

So far, Altmetric has seen 16 patents that reference this research output.

Methods for treating pancreatic cancer using combination therapies

Grant US-12364691-B2

United States of America

22 Jul 2025

Combination therapy for cancer treatment

Grant US-11844795-B2

United States of America

19 Dec 2023

Methods for treating pancreatic cancer using combination therapies

Grant US-11369597-B2

United States of America

28 Jun 2022

Cholinergic agonism for the treatment of pancreatic cancer

Grant US-11344534-B2

United States of America

31 May 2022

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 12 additional patents.